READ MORE: Obstructive Sleep Apnea Status Affects Glymphatic System Function and Cognitive Function
Top Clinical Takeaways
- The positive predictive value of using RBD ICD code for iRBD was reported as 73.25% from the review of electronic health records.
- Patients with iRBD had a significantly higher risk of being diagnosed with neurodegenerative parkinsonian disorders or dementia in real-world settings.
- The study demonstrated the feasibility of using statistical models developed from EHR data to accurately predict iRBD in outpatient settings.
Additional findings showed that the iRBD group had a higher risk of neurodegenerative parkinsonian disorders or dementia (subdistribution HR, 10.4; 95% CI, 2.5-43.1) compared with the no iRBD group. Notably, authors reported that the LASSSO prediction model for iRBD had an Area Under the Receiver Operating Characteristic Curve of 0.844 (95% CI, 0.806-0.880). Prior research shows that iRBD carries an increased risk for neurodegenerative parkinsonian disorders or dementia, but clinicians have had difficulty with accurately screening for it in the patient community. Thus, healthcare data provided by EHR may offer the opportunity to identify large numbers of cases in iRBD among outpatients.1
According to a previous review study published in the Journal of Neurology, results showed a substantial delay before neurologist are consulted about iRBD.1 The literature also revealed that patients were unaware of their nocturnal signs and the symptoms described could mimic or masquerade other sleep disorders. In addition, general providers did not recognize the significance of the symptoms or consider the diagnosis of iRBD since it was considered a lesser-known condition. Therefore, authors of the review recommended that neurologists and other clinicians diagnosing iRBD should conduct questionnaires to help them make a more "probable diagnosis" but this approach should not be used as the only diagnostic tool for iRBD.
As patients live longer worldwide, the number of those at risk of neurodegenerative diseases is to dramatically increase. Thus, the detection of iRBD presents an important opportunity for clinicians to intervene early in the condition, through therapies or risk modification, to adjust its trajectory or even prevent the development of neurodegenerative diseases in the future. Authors from the prior review noted that there is an increasing interest in pharmaceutical clinical trials for iRBD that is further increasing the criticalness of diagnosis and rasing awareness of the key role neurologists play to accurately diagnosis this disorder early on.
Click here for more coverage of SLEEP 2024.
REFERENCES
1. Chahine L, Ratner D, Palmquist A, et al. A REM Sleep Behavior Disorder Diagnostic Code Accuracy and Implications in the Outpatient Setting. Presented at: 2024 SLEEP Annual Meeting; June 1-5; Houston, Texas. Abstract 0711.
2. Bramich S, King A, Kuruvilla M, Naismith SL, Noyce A, Alty J. Isolated REM sleep behaviour disorder: current diagnostic procedures and emerging new technologies. J Neurol. 2022;269(9):4684-4695. doi:10.1007/s00415-022-11213-9